How to buy Alkermes stock (ALKS)

Alkermes is a drug manufacturers - specialty & generic business based in the US. Alkermes shares (ALKS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $29.71 – a decrease of 2.62% over the previous week. Alkermes employs 2,100 staff and has a trailing 12-month revenue of around $1.5 billion.

Our top picks for where to buy Alkermes stock

Buy Alkermes stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Alkermes stock price (NASDAQ: ALKS)

Use our graph to track the performance of ALKS stocks over time.

Alkermes shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$29.71
52-week range	$22.90 - $32.88
50-day moving average more info button	$28.62
200-day moving average more info button	$26.66
Wall St. target price	$34.08
PE ratio more info button	13.131
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$2.29

Is it a good time to buy Alkermes stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Alkermes price performance over time

Historical closes compared with the close of $29.71 from 2024-12-20

1 week (2024-12-13)	-2.62%
1 month (2024-11-22)	3.23%
3 months (2024-09-20)	4.06%
6 months (2024-06-21)	19.08%

1 year (2023-12-22)	6.41%
2 years (2022-12-22)	16.01%
3 years (2021-12-22)	25.25%
5 years (2019-12-20)	42.02%

Is Alkermes stock undervalued or overvalued?

Valuing Alkermes stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Alkermes's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Alkermes's P/E ratio

Alkermes's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, Alkermes shares trade at around 13x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Alkermes's EBITDA

Alkermes's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $358.8 million.

The EBITDA is a measure of a Alkermes's overall financial performance and is widely used to measure a its profitability.

Alkermes financials

Revenue TTM	$1.5 billion
Operating margin TTM	27.7%
Gross profit TTM	$893.7 million
Return on assets TTM	8.98%
Return on equity TTM	29.23%
Profit margin	22.15%
Book value	$7.99
Market Capitalization more info button	$4.9 billion

TTM: trailing 12 months

Alkermes share dividends

We're not expecting Alkermes to pay a dividend over the next 12 months.

Have Alkermes's shares ever split?

Alkermes's shares were split on a 2:1 basis on 14 May 2000 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Alkermes shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Alkermes shares which in turn could have impacted Alkermes's share price.

Alkermes share price volatility

Over the last 12 months, Alkermes's shares have ranged in value from as little as $22.9 up to $32.88. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alkermes's is 0.435. This would suggest that Alkermes's shares are less volatile than average (for this exchange).

Alkermes overview

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N. V. , Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products.

Frequently asked questions

null
What percentage of Alkermes is owned by insiders or institutions?
Currently 1.297% of Alkermes shares are held by insiders and 113.818% by institutions. How many people work for Alkermes?
Latest data suggests 2,100 work at Alkermes. When does the fiscal year end for Alkermes?
Alkermes's fiscal year ends in December. Where is Alkermes based?
Alkermes's address is: Connaught House, Dublin, Ireland, D04 C5Y6 What is Alkermes's ISIN number?
Alkermes's international securities identification number is: USG017671052 What is Alkermes's CUSIP number?
Alkermes's Committee on Uniform Securities Identification Procedures number is: 01642T108